LagoMed LipoReduce

LagoMed LipoReduce

Giving the rising epidemic of metabolic syndrome which consists of a combination of risk factors such as insulin resistance, high blood pressure, high triglycerides, and low high – density lipoprotein (HDL), increases one’s risk for diabetes and cardiovascular disease especially in obese patients.

Regulated as a drug in several European countries where it is approved for the treatment of diabetes – related complications, certain complications of alcoholism, and a variety of liver conditions, lipoic acid has emerged as an important component of each individual’s health maintenance regime.

to view content or register to become member.